BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 16494106)

  • 1. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.
    Orlando A; Modesto I; Castiglione F; Scala L; Scimeca D; Rispo A; Teresi S; Mocciaro F; Criscuoli V; Marrone C; Platania P; De Falco T; Maisano S; Nicoli N; Cottone M
    Eur Rev Med Pharmacol Sci; 2006; 10(1):17-22. PubMed ID: 16494106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.
    Baillet P; Cadiot G; Goutte M; Goutorbe F; Brixi H; Hoeffel C; Allimant C; Reymond M; Obritin-Guilhen H; Magnin B; Bommelaer G; Pereira B; Hordonneau C; Buisson A
    World J Gastroenterol; 2018 Feb; 24(5):641-650. PubMed ID: 29434453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
    Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
    Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
    J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.
    Lasson A; Strid H; Ohman L; Isaksson S; Olsson M; Rydström B; Ung KA; Stotzer PO
    J Crohns Colitis; 2014 Aug; 8(8):789-95. PubMed ID: 24418661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
    Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of faecal calprotectin to predict post-operative recurrence in Crohńs disease.
    Herranz Bachiller MT; Barrio Andres J; Fernandez Salazar L; Ruiz-Zorrilla R; Sancho Del Val L; Atienza Sanchez R
    Scand J Gastroenterol; 2016; 51(6):720-6. PubMed ID: 26758472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between endoscopy and intestinal ultrasound for the evaluation of postoperative recurrence of Crohn's disease.
    Yebra Carmona J; Poza Cordón J; Suárez Ferrer C; Martín Arranz E; Lucas Ramos J; Andaluz García I; Sánchez Azofra M; Rueda García JL; Martín Arranz MD
    Gastroenterol Hepatol; 2022 Jan; 45(1):40-46. PubMed ID: 33746025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up.
    Delefortrie Q; Schatt P; Grimmelprez A; Gohy P; Deltour D; Collard G; Vankerkhoven P
    Clin Biochem; 2016 Feb; 49(3):268-73. PubMed ID: 26506117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
    Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
    Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn's Disease.
    Liu R; Guo Z; Cao L; Wang Z; Gong J; Li Y; Zhu W
    Dis Colon Rectum; 2019 Mar; 62(3):318-326. PubMed ID: 30451756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn's disease patients with anastomotic strictures.
    Lopes S; Andrade P; Rodrigues-Pinto E; Afonso J; Macedo G; Magro F
    World J Gastroenterol; 2017 Sep; 23(35):6482-6490. PubMed ID: 29085198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.